Stock Ratings / Health Care / OSTX / dividends

ZYBT (40) RNXT (31) FBIO (39) MNOV (30) ⌘ Pro Terminal →

OS Therapies Incorporated (OSTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.24 -4.61% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.23

OS Therapies Incorporated (OSTX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $67.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OSTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, OS Therapies Incorporated (NYSE: OSTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.24 (-4.61% 1D, market cap $67.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OSTX ranks #481 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OSTX compare to ZYBT and RNXT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZYBT (Zhengye Biotechnology Holding Limited (Class A)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OSTX?

▼

Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $0 in revenue, -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.23 (-1.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OSTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY OSTX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 33.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.62-18.5% Next Q

Q2 (-2Q)

Grade D$1.32-5.3% Next Q

Q3 (-1Q)

Grade D$1.25-0.8% Next Q

Current

Grade D-$1.24-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OSTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OSTX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.57) and Max Pain ($1.30) forces dealer call-delta covering toward $2.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OSTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OSTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OSTX)

✓Walkthrough of OSTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OSTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.06%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.27H $1.28L $1.21C $1.24VOL 317.5K

RES: $1.84SUP: $1.19SMA50: $1.57SMA200: $1.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OSTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OSTX Butterfly Map → + Track OSTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OSTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OSTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OSTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OSTX)

Health Care Rank #481 of 1016 ⚔️ ZYBT vs OSTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OSTX vs. ZYBT, RNXT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OS Therapies Incorporated (OSTX) ranks #481 by composite RQD confidence (42/100, grade D-) and #711 by equity capitalization ($67.6M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OSTX ACTIVE OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	Benchmark Subject
ZYBT Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	/zybt-vs-ostx →
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-ostx →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-ostx →
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-ostx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001795091

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OS Therapies Incorporated (OSTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.8M, operating cash flow of -$14.2M, and free cash flow of -$14.2M (-95.5% YoY). On the balance sheet, OSTX closed FY2025 with $6.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$28.8M	-$14.2M	-$14.2M	$6.8M	—
FY2024 (FY)	2024-12-31	$0	-$8.9M	-$7.3M	-$7.3M	$5.5M	—
FY2023 (FY)	2023-12-31	$0	-$7.8M	-$3.0M	-$3.0M	—	—

3. OSTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OSTX compare to ZYBT and RNXT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OSTX?

Where is OSTX trading relative to its 50-day, 200-day, and 52-week technical levels?

OSTX last traded at $1.24 (-4.61% on volume of 321,734 shares), positioning the stock -21.02% below its 50-day simple moving average ($1.57) and -20.51% below its 200-day simple moving average ($1.56). Across its 52-week range of $1.15 to $2.25, OSTX sits at the 8.2% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.39).

OSTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does OSTX pay a dividend and is it safe?

OS Therapies Incorporated (OSTX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: OSTX RQD Cockpit OSTX 12M Forecast OSTX Earnings & Move OSTX Dividends & DRIP OSTX Insiders & 13F OSTX Whale Options OSTX Profit Sankey OSTX News & Why